UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

278P Full-coverage radiotherapy for prostate cancer patients with oligometastases

Annals of oncology, 2023-11, Vol.34, p.S1580-S1581

2023

Volltextzugriff (PDF)

780P Safety and efficacy of endostar combined with platinum-based chemotherapy in the first-line treatment of recurrence and metastatic cervical cancer: A single-arm, prospective phase II study

Annals of oncology, 2021-09, Vol.32, p.S754-S754

2021

Volltextzugriff (PDF)

506PTPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Annals of oncology, 2019-10, Vol.30 (Supplement_5)

2019

Volltextzugriff (PDF)

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Annals of oncology, 2019-10, Vol.30, p.v190-v191

2019

Volltextzugriff (PDF)

506P - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

Annals of oncology, 2019-10, Vol.30, p.v190-v191

2019

Volltextzugriff (PDF)

175TiP A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation

Annals of oncology, 2022-11, Vol.33, p.S1502

2022

Volltextzugriff (PDF)

Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy

Annals of oncology, 2013-05, Vol.24 (5), p.1312-1319

2013

Volltextzugriff (PDF)

2024P - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma

Annals of oncology, 2019-10, Vol.30 (Supplement_5), p.v809-v809

2019

Volltextzugriff (PDF)

1740P Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial

Annals of oncology, 2024-09, Vol.35, p.S1040-S1040

2024

Volltextzugriff (PDF)

106P Comparative analysis of urinary and tissue tumor DNA in muscle-invasive bladder cancer by boosted whole-exome sequencing

Annals of oncology, 2022-09, Vol.33, p.S587

2022

Volltextzugriff (PDF)

Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study

Annals of oncology, 2019-04, Vol.30, p.ii48-ii48

2019

Volltextzugriff (PDF)

[18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma

Annals of oncology, 2019-10, Vol.30, p.v809

2019

Volltextzugriff (PDF)

2402P Urine-based comprehensive genomic profiling reveals mutational landscape in real-world patients with bladder cancer

Annals of oncology, 2023-10, Vol.34, p.S1222-S1222

2023

Volltextzugriff (PDF)

2401P Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)

Annals of oncology, 2023-10, Vol.34, p.S1222-S1222

2023

Volltextzugriff (PDF)

428P Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer

Annals of oncology, 2021-09, Vol.32, p.S548-S548

2021

Volltextzugriff (PDF)

275P Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer

Annals of oncology, 2024-09, Vol.35, p.S330-S331

2024

Volltextzugriff (PDF)

815MO A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety

Annals of oncology, 2024-09, Vol.35, p.S602-S602

2024

Volltextzugriff (PDF)

Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B

Annals of oncology, 2018-02, Vol.29 (2), p.516-517

2018

Volltextzugriff (PDF)

576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study

Annals of oncology, 2024-09, Vol.35, p.S467-S468

2024

Volltextzugriff (PDF)

1830P CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study

Annals of oncology, 2023-10, Vol.34, p.S991-S991

2023

Volltextzugriff (PDF)

Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients

Annals of oncology, 2019-11, Vol.30, p.ix137

2019

Volltextzugriff (PDF)

1765P The lack of KRAS variation and its therapeutic implication in MSI-H colorectal cancer with NTRK fusion

Annals of oncology, 2021-09, Vol.32, p.S1212-S1212

2021

Volltextzugriff (PDF)

LBA61 Conventional oral morphine vs. IV patient-controlled analgesia (IPCA) with either hydromorphone (HM) continuous infusion plus rescue dose (CIRD) or HM bolus-only (BO) for severe cancer pain: A randomized phase III study

Annals of oncology, 2024-09, Vol.35, p.S1251-S1251

2024

Volltextzugriff (PDF)

1318P Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)

Annals of oncology, 2024-09, Vol.35, p.S839-S839

2024

Volltextzugriff (PDF)

129P Integrating large data to unveil vulnerabilities for patients with hot tumors resistant to checkpoint inhibition

Annals of oncology, 2024-09, Vol.35, p.S266-S267

2024

Volltextzugriff (PDF)

1 – 25 von 47

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieAnnals Of Oncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(47)

Publikationsform

Artikel
(47)

Sprache

Englisch
(47)

Erscheinungsjahr

n.n

Thema

Humans
(3)
Life Sciences & Biomedicine
(3)
Oncology
(3)
Science & Technology
(3)
Adult
(2)
Aged
(2)
Aged, 80 And Over
(2)
Antineoplastic Agents
(2)
Biological And Medical Sciences
(2)
Carcinoma, Non-Small-Cell Lung - Radiotherapy
(2)
Female
(2)
Lung Neoplasms - Radiotherapy
(2)
Male
(2)
Medical Sciences
(2)
Middle Aged
(2)
Non-Small-Cell Lung Cancer
(2)
Original
(2)
Pharmacology. Drug Treatments
(2)
Pneumology
(2)
Tumors Of The Respiratory System And Mediastinum
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Neu hinzugefügt

... seit 90 Tagen
(8)

Menü

Weitere Dienste

Einstellungen

278P Full-coverage radiotherapy for prostate cancer patients with oligometastases

780P Safety and efficacy of endostar combined with platinum-based chemotherapy in the first-line treatment of recurrence and metastatic cervical cancer: A single-arm, prospective phase II study

506PTPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

506P - TPX-0046 is a novel and potent RET/SRC inhibitor for RET-driven cancers

175TiP A prospective phase II study to investigate the efficacy and safety of olaparib plus abiraterone and prednisone combination therapy in mHSPC patients with HRR gene mutation

Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy

2024P - [18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma

1740P Surufatinib combined with gemcitabine in soft tissue sarcoma (STS) patients failed with anthracyclines chemotherapy or monotherapy post-anlotinib progression: A multi-center, phase II trial

106P Comparative analysis of urinary and tissue tumor DNA in muscle-invasive bladder cancer by boosted whole-exome sequencing

Potential resistance mechanisms using next generation sequencing from Chinese EGFR T790M+ non-small cell lung cancer patients with primary resistance to osimertinib: A multicenter study

[18F]-FDG PET/CT in predicting PD-L1 status in nasopharyngeal carcinoma

2402P Urine-based comprehensive genomic profiling reveals mutational landscape in real-world patients with bladder cancer

2401P Detection of molecular recurrence in early-stage bladder cancer patients using a urinary tumor DNA assay after transurethral resection of bladder tumor (TURBT)

428P Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer

275P Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer

815MO A prospective study of orelabrutinib plus obinutuzumab (O2) in treatment-naïve marginal zone lymphoma (MZL): Preliminary analysis on efficacy and safety

Increase of programmed death ligand 1 in non-small-cell lung cancers with chronic hepatitis B

576P Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study

1830P CBP-1018, a bi-ligand-drug conjugate treated in patients with advanced solid tumors: A phase I, multi-center, open-label, dose-escalation and dose expansion study

Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients

1765P The lack of KRAS variation and its therapeutic implication in MSI-H colorectal cancer with NTRK fusion

LBA61 Conventional oral morphine vs. IV patient-controlled analgesia (IPCA) with either hydromorphone (HM) continuous infusion plus rescue dose (CIRD) or HM bolus-only (BO) for severe cancer pain: A randomized phase III study

1318P Four-year outcomes from GEMSTONE-302 study: First-line sugemalimab plus platinum-based chemotherapy in metastatic non-small cell lung cancer (NSCLC)

129P Integrating large data to unveil vulnerabilities for patients with hot tumors resistant to checkpoint inhibition

Aktive Filter

Suchergebnisse filtern